retatrutide phase 2 trial type 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide Severe Obesity Trial Shows

u , Change in body weight

Guilln-Lozoya also hypothesized that GLP1 drugs may eventually emerge as a adjunctive strategy for men with functional hypogonadism that is related to obesity and metabolic disease

Eight participants completed the study on a lower medication dose, and 11 discontinued the study medication but remained in the study

This allows your provider to determine whether GLP-1 therapy may be appropriate based on your individual goals and health profile

They address the metabolic dysfunction that drives type 2 diabetes in ways that insulin alone cannot

Understanding the healing process and factors affecting results enables better decision-making and satisfaction with outcomes